Contribution of Angiotensin Converting Enzyme Gene Polymorphism to the Action of Angiotensin II Receptor Antagonist (CS-866)
スポンサーリンク
概要
- 論文の詳細を見る
- 2002-03-31
著者
-
Ieiri Ichiro
Department Of Clinical Pharmacokinetics Graduate School Of Pharmaceutical Sciences Kyushu University
-
Ieiri I
Department Of Hospital Pharmacy Faculty Of Medicine Tottori University
-
Ogihara Toshio
大阪大学大学院医学系研究科加齢医学
-
URAE Akinori
医療法人相生会臨床薬理センター
-
OKADA Mitsuko
医療法人相生会臨床薬理センター
-
IEIRI Ichiro
九州大学大学院薬学研究所薬物動態学
-
HIGUCHI Shun
九州大学大学院薬学研究所薬物動態学
-
HISAOKA Masafumi
三共株式会社薬剤動態研究所
-
TAJIMA Masazo
三共株式会社薬剤動態研究所
-
NAKANO Shigeyuki
大分医科大学臨床薬理学
-
Urae Akinori
Kyushu Pharmacology Research Clinic
-
Tajima M
三共株式会社薬剤動態研究所
-
Higuchi S
Department Of Clinical Pharmacokinetics Graduate School Of Pharmaceutical Sciences Kyushu University
-
Higuchi S
Kyushu Univ. Fukuoka Jpn
-
Higuchi Shun
Department Of Clinical Pharmacokinetics Graduate School Of Pharmaceutical Sciences Kyushu University
関連論文
- Polymorphism of MDR1 Gene in healthy Japanese Subjects : A Novel SNP with an Amino Acid Substitution (Glu108Lys)
- Contribution of Angiotensin Converting Enzyme Gene Polymorphism to the Action of Angiotensin II Receptor Antagonist (CS-866)
- Cerebral Acetylcholine Levels and Long-Term Spatial Cognitive Impairment Following Middle Cerebral Artery Occlusion in Rats
- Relationship between Patients' Clinical Background and Lithium Concentration in Plasma : An Analysis of TDM Database in a University Hospital in Japan
- Dubin-Johnson 症候群患者に認めたABCC2遺伝子の部分欠損(exon 7 全域)例
- FORMATION OF HIGHLY ANALGESIC MORPHINE-6-GLUCURONIDE FOLLOWING PHYSIOLOGIC CONCENTRATION OF MORPHINE IN HUMAN BRAIN
- A New Computerized Test Battery to Evaluate Drug Effects on Psychomotor Performance : Lorazepam-induced Impaired Performance in Healthy Volunteers
- Pharmacokinetic interaction between pravastatin and olmesartan in relation to SLCO1B1 polymorphism
- Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin
- Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy